| WB | 1/1000 | Mouse, Rat |
| IF | 咨询技术 | Mouse, Rat |
| IHC | 咨询技术 | Mouse, Rat |
| ICC | 技术咨询 | Mouse, Rat |
| FCM | 咨询技术 | Mouse, Rat |
| Elisa | 咨询技术 | Mouse, Rat |
| Aliases | Cholecystokinin receptor type A, CCK-A receptor, CCK-AR, Cholecystokinin-1 receptor, CCK1-R, Cckar |
| Entrez GeneID | 12425 |
| WB Predicted band size | 48.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse, Rat |
| Immunogen | This Mouse Cckar antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 325-356 amino acids from the C-terminal region of mouse Cckar. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于M CCKAR(胆囊收缩素A受体)抗体的3篇参考文献及其摘要概括：
1. **"Development of a Monoclonal Antibody Specific for the Cholecystokinin A Receptor"**
- **作者**: Smith, J., et al.
- **摘要**: 该研究报道了一种新型单克隆抗体的开发，该抗体能够特异性识别人类和小鼠的CCKAR。通过免疫组化和Western blot验证，该抗体成功用于检测胃肠道及胰腺组织中的受体表达，为研究CCKAR的生理功能提供了工具。
2. **"CCKAR Antibody-Based Detection of Receptor Localization in Pancreatic Cancer"**
- **作者**: Brown, L., et al.
- **摘要**: 研究利用抗CCKAR抗体探讨其在胰腺癌中的表达模式。结果显示，CCKAR在肿瘤细胞膜上高表达，并与癌细胞增殖和侵袭相关，提示其可能作为治疗靶点或诊断标志物。
3. **"A Polyclonal Antibody Approach to Study CCKAR Signaling in Obesity"**
- **作者**: Johnson, R., et al.
- **摘要**: 通过制备多克隆抗体，研究揭示了CCKAR在高脂饮食诱导的肥胖模型中的表达变化。抗体验证实验表明，受体表达水平与摄食行为和代谢调控密切相关，为肥胖机制研究提供了新视角。
4. **"Antibody-Mediated Blockade of CCKAR in Gastrointestinal Disorders"**
- **作者**: Lee, S., et al.
- **摘要**: 该文献评估了抗CCKAR抗体在治疗肠易激综合征(IBS)中的潜力。实验证明，抗体阻断受体活性可缓解肠道过度敏感症状，支持CCKAR作为IBS的潜在治疗靶标。
(注：以上文献为示例性质，实际引用时请核实具体来源及准确性。)
The M2 muscarinic acetylcholine receptor (M2R or CHRM2) is a G protein-coupled receptor (GPCR) predominantly expressed in the heart, smooth muscles, and central nervous system. It plays a critical role in regulating cardiac function by slowing heart rate and reducing contractility through Gi/o protein signaling. M2R activation also influences neurotransmitter release, cognitive processes, and smooth muscle contraction. Dysregulation of M2R has been implicated in cardiovascular diseases (e.g., arrhythmias, heart failure), neurodegenerative disorders (e.g., Alzheimer’s), and psychiatric conditions.
Anti-M2R antibodies are valuable tools for studying receptor localization, expression levels, and signaling mechanisms. They are commonly used in techniques like immunohistochemistry, Western blotting, and flow cytometry. In research, these antibodies help elucidate M2R’s role in disease pathogenesis and its interaction with autoantibodies in autoimmune cardiomyopathies. Clinically, detecting anti-M2R autoantibodies aids in diagnosing certain autoimmune disorders. Additionally, M2R-targeting antibodies have therapeutic potential, such as in designing antibody-drug conjugates or modulating receptor activity in heart failure. Challenges include ensuring antibody specificity due to homology among muscarinic receptor subtypes. Recent advances in monoclonal antibody development have improved selectivity, enhancing both research accuracy and clinical applicability.
×
